Chest
-
Pleural Disease/Pleural Effusion PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To find biochemical parameters in pleural fluid, that may exceed the performance of Light criteria to discriminate transudates and exudates. Assess whether the clinical diagnosis exceeds or not biochemical parameters of pleural fluid to differentiate transudates and exudates. ⋯ The following authors have nothing to disclose: Carolina Gotera, Deisy Barrios Barreto, Patricia Lazo Meneses, Rosa Mirambeaux Villalona, Carolina Jurkojc Mohremberger, Esteban Perez Rodriguez, Salvador Diaz Lobato, Sagrario Mayoralas AlisesNo Product/Research Disclosure Information.
-
Lung Cancer Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Lung cancer remains the leading cause of cancer deaths wordlwide. There is a limited data evaluating overall five years lung cancer survival. The aim of this study is to describe the characteristics of our patients with lung cancer and the five years survival rate in our hospital. ⋯ The following authors have nothing to disclose: Rosa Maria Ortiz Comino, Noemi Burgos Guadix, Rosa Lina De los Santos de Lopez, Ana Dolores Romero Ortiz, Manuel De VegaNo Product/Research Disclosure Information.
-
Bronchology CasesSESSION TYPE: Case ReportsPRESENTED ON: Sunday, March 23, 2014 at 09:00 AM - 10:00 AMPURPOSE: Bronchial Anthracofibrosis (BAF) is deposition of anthracotic pigment in the bronchial wall resulting in fibrosis and stenosis of a bronchus. BAF is commonly associated with tuberculosis and smoke inhalation. We report two cases of BAF. ⋯ The following authors have nothing to disclose: Amitesh Agarwal, Jose Valle, Gulshan Sharma, Shawn NishiNo Product/Research Disclosure Information.
-
DVT/PE PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Current VTE prophylaxis guidelines strongly promote risk assessment on the individual level. The IMPROVE VTE risk assessment model (RAM) is a composite score formulated to predict individual VTE risk during hospitalization. It is developed from a derivation cohort and has preliminary validation. This score sums 7 risk factors into risk categories: 0-1-Low Risk, 2-3-Moderate risk, >=4-high risk. In this study we aimed to validate the IMROVE VTE RAM using billing and EMR data from 2 tertiary medical centers in the North Shore-LIJ Health System ⋯ David Rosenberg: Consultant fee, speaker bureau, advisory committee, etc.: Honorarium for consulting from Beohringer Ingelheim, Daiichi Sankyo , Grant monies (from industry related sources): Local PI on APEX trial, Portola The following authors have nothing to disclose: Ann Eichorn, Mauricio Alarcon, Lauren McCullagh, Alex SpyropoulosNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The aim of our study was to look for the factors that affect survival of patients with COPD exacerbations admitted in a pulmonology department of a Portuguese central hospital. ⋯ The following authors have nothing to disclose: Daniel Coutinho, Inês Franco, Margarida Dias, Maria Tzer, Maria BritoNo Product/Research Disclosure Information.